Traditional cancer research involves the study of cancer biology at the cellular, organ, and systemic level. In light of the technological developments in engineering, physics, lasers, imaging systems, biosensing and bioMEMS devices, advanced microscopy systems, drug delivery systems and nanotechnology, the Biomedical Technology Program (BTP) is organized with the goals of capitalizing on the tools and technologies developed by engineering and physical scientists by applying these devices and concepts towards the overall reduction of cancer morbidity and mortality. Currently, the BTP incorporates five scientific themes that capture the breadth of expertise and technologies available to the program. The five themes are: (1) Research and Diagnostic Technologies, (2) Technologies for Whole Body/Organ Imaging, (3) Technologies for Cancer Therapy, (4) Biomarker Discovery and Development, and (5) Biosensing Technologies. The BTP has 34 members with expertise across broad areas of engineering science, physical science and medical science. The BTP includes members from eleven different research and academic departments and four different schools and research centers at UC Davis and Lawrence Livermore National Laboratory (LLNL). This includes the College of Engineering (in particular the Departments of Biomedical Engineering and Mechanical and Aeronautical Engineering), the School of Medicine (in particular Radiology, Radiation Oncology, Internal Medicine, General Surgery, Neurological Surgery), the School of Veterinary Medicine, and LLNL. The BTP also includes members who are primarily clinicians, who play an important role in ensuring the program is addressing cancer-relevant questions, and a critical role in helping technical members of the program move new technologies into successful early phase clinical testing in patients. Thus, the expertise of our members spans a wide range of scientific disciplines and fields bridging from the engineering and physical sciences to the medical and veterinary sciences. PROGRAM ASPECTS Co-leaders: Simon Cherry, PhD; Laura Marcu, PhD Members: 34 Total Grant Funding (ADC): $7.8 million Total Peer-Reviewed Funding (ADC): $7.2 million Total NCI funding (ADC): $3.0 million Total No. Publications: 644 Inter-programmatic publications: 235 (37%) Intra-programmatic publications: 121 (19%) Multi-institutional publications: 262 (41%)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-18
Application #
9993310
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Yuan, Ye; He, Yixuan; Bo, Ruonan et al. (2018) A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 10:21634-21639
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987
Xue, Xiangdong; Huang, Yee; Bo, Ruonan et al. (2018) Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nat Commun 9:3653
Knight, Jennifer F; Sung, Vanessa Y C; Kuzmin, Elena et al. (2018) KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer. Cell Rep 22:3191-3205
Couto, K M; Moore, P F; Zwingenberger, A L et al. (2018) Clinical characteristics and outcome in dogs with small cell T-cell intestinal lymphoma. Vet Comp Oncol 16:337-343
Dou, John; Schmidt, Rebecca J; Benke, Kelly S et al. (2018) Cord blood buffy coat DNA methylation is comparable to whole cord blood methylation. Epigenetics 13:108-116
Xue, Xiangdong; Huang, Yee; Wang, Xinshuai et al. (2018) Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy. Biomaterials 161:203-215
Ho, Pui Yan; Duan, Zhijian; Batra, Neelu et al. (2018) Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther 365:494-506
Zuo, Yang; Qi, Jinyi; Wang, Guobao (2018) Relative Patlak plot for dynamic PET parametric imaging without the need for early-time input function. Phys Med Biol 63:165004
McGee, Heather M; Daly, Megan E; Azghadi, Sohelia et al. (2018) Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys 101:1259-1270

Showing the most recent 10 out of 836 publications